Trust Investment Advisors Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Trust Investment Advisors reduced its stake in Eli Lilly and Co by 3.46% during the most recent quarter end. The investment management company now holds a total of 33,525 shares of Eli Lilly and Co which is valued at $2,700,774 after selling 1,200 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Eli Lilly and Co makes up approximately 3.00% of Trust Investment Advisors’s portfolio.

Other Hedge Funds, Including , Feltz Wealth Plan reduced its stake in LLY by selling 2,150 shares or 71.67% in the most recent quarter. The Hedge Fund company now holds 850 shares of LLY which is valued at $68,476.Whittier Trust Co Of Nevada Inc boosted its stake in LLY in the latest quarter, The investment management firm added 180 additional shares and now holds a total of 16,219 shares of Eli Lilly and Co which is valued at $1,344,393. Eli Lilly and Co makes up approx 0.15% of Whittier Trust Co Of Nevada Inc’s portfolio.Investment Partners Ltd Oh Adv reduced its stake in LLY by selling 4,295 shares or 36.15% in the most recent quarter. The Hedge Fund company now holds 7,587 shares of LLY which is valued at $602,104. Eli Lilly and Co makes up approx 0.59% of Investment Partners Ltd Oh Adv’s portfolio.

Eli Lilly and Co opened for trading at $80.33 and hit $80.62 on the upside on Monday, eventually ending the session at $80.26, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 27,80,381 shares. Company has a market cap of $88,594 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.